Mounjaro is a dual medication (namely, a GLP-1 receptor agonist and, at the same time, a GIP receptor agonist), meaning it not only targets the GLP-1 receptor-like Ozempic but also stimulates the glucose-dependent insulinotropic polypeptide (GIP) receptor
Should Phase 3 data prove favourable, a regulatory submission could follow, though the timing remains uncertain and no predictions should be drawn from the approval timelines of other medicine classes
Nikitovic D, Mytilinaiou M, Berdiaki A, Karamanos NK, Tzanakakis GN
No single mechanism has been confirmed, but several possible explanations exist
In order to create an oral version of the popular weight loss treatment, semaglutide needs to be delivered through the gastrointestinal tract without being degraded by enzymes
For patients with specific genetic profiles, tirzepatide alone (at $289/mo month-to-month, or from $249/mo on the 6-month plan) may unlock better results than semaglutide